SCHEMBL26360003

SCHEMBL26360003

Cc1cc(OCc2ccccc2)c(C)c(F)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.56
▸ MAPT P10636 2/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ MRGPRX4 Q96LA9 3/20 0.50
▸ MAPK14 Q16539 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ STAT3 P40763 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ KDM1A O60341 4/20 0.44
▸ FFAR4 Q5NUL3 1/20 0.44
▸ LIPE Q05469 1/20 0.44
▸ AOC3 Q16853 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ RXRA P19793 1/20 0.42
▸ RXRB P28702 1/20 0.42
▸ RXRG P48443 1/20 0.42
▸ BRD4 O60885 2/20 0.41
▸ PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23099885 0.83 MAPT (0.49) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL25081934 0.80 MAPT (0.64) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL8761479 0.80 MAPT (0.51) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL8755664 0.80 MAPT (0.51) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL8419308 0.79 MAPT (0.59) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL1539870 0.79 MAPT (0.59) L3MBTL1MAPTTDP1MAPK1MAPK14
SCHEMBL17616641 0.78 MRGPRX4 (0.36) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL24074149 0.78 L3MBTL1 (0.58) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL24446054 0.78 MAPT (0.53) L3MBTL1MAPTTDP1MAPK1MRGPRX4
SCHEMBL26095806 0.78 MAPT (0.49) L3MBTL1MAPTTDP1MAPK1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303495-A9 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303495-A9 PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF SCN11A, HCN4, CACNA1F L3MBTL1 4591/4885MAPT 717/4885TDP1 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback